US$ 27.35
bpc 157 for hashimoto's Multifunctionality and Possible Medical Application of the Peptide—Literature and Patent Review What Is BPC-157? A Medical
Description
Frequency: Once per week (subcutaneous), same day each week

The International Journal of Developmental Biology, 62 (6-7-8), 491-505

The findings: 52% contained substances not listed on the label, and 39% contained a different dose than advertised

While these results were promising, Retatrutide remains under research evaluation and is not an FDA-approved medication